Increasing-medication options in low threshold Opioid Agonist Treatment 

LASSO is a low threshold clinic for Opioid Agonist Treatment (OAT) for individuals dependent on heroin and other opioids who do not engage with the conventional offerings of Medication-Assisted Rehabilitation (MAR).

From 2010 until 2017, only the combination preparation of buprenorphine and naloxone was available as a medication for OAT at LASSO. As of spring 2017, buprenorphine monopreparation (Subutex Ⓡ) became accessible at LASSO, and from 2020, methadone and the long-acting buprenorphine (Buvidal) became available.

We aim to investigate whether a broader array of medications in low-threshold OAT enhances treatment outcomes and leads to an improvement in the well-being of more individuals with opioid dependence.

LASSO is a collaborative effort between the Agency for Welfare and Social Services (Oslo Municipality), and the Department of Addiction and Substance Abuse Treatment (Oslo University Hospital Health Trust).

Link:

Medikamentvalg ved lavterskeltiltak - Oslo universitetssykehus HF